PHASE　II　CLINICAL　TRIAL　OF　LASTET　CAPSULE　IN　COMBINATION　CHEMOTHERAPY　OF　MALIGNANT　TUMORSIN　CHINA  

作　　者：张天泽 印季良 何友兼 王德元 王怡 

出　　处：《Chinese Journal of Cancer Research》1995年第3期181-186,共6页中国癌症研究（英文版）

摘　　要：This study reports the efficacy of prolonged administration of oral etoposide in the treatment of 86 cases with solid tumor,malignant lymphoma and other cancer.The oral etoposide used was the Lastet capsule (Las-c).An overall response rate(RR)of 62.8% was achieved with CR rate being 23.3% and PR rate 39.5%. Different combination chemotherapy regimens led to different response rates but no significant difference was found. The Las-C containing regimens used in this study have not caused any serious side effects.This study reports the efficacy of prolonged administration of oral etoposide in the treatment of 86 cases with solid tumor,malignant lymphoma and other cancer.The oral etoposide used was the Lastet capsule (Las-c).An overall response rate(RR)of 62.8% was achieved with CR rate being 23.3% and PR rate 39.5%. Different combination chemotherapy regimens led to different response rates but no significant difference was found. The Las-C containing regimens used in this study have not caused any serious side effects.

关 键 词：Phase II clinical trial Las-C Combination chemotherapy. 

分 类 号：R730.5[医药卫生—肿瘤]